When Leronlimab is approved for the combo, NCCN can recommend the use of Leronlimab off-label for cancers where there is only a Phase I study, only to have proven safety and efficacy. The insurances accept the NCCN recommendations, and if a drug shows efficacy we immediately see how many people are responding, the NP received 10 emails in one day.